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Sary With the aim of increasing the dose intensity of chemotherapy in breast cancer, 14 patients with
stage II-IV breast cancer were treated with FEC chemotherapy at 2 week intervals together with granulocyte
colony-stimulating factor (G-CSF) 5 gg kg-' s.c. on days 2-14. Five of six patients completed six courses of
5-fluorouracil 600 mg m-2, epirubicn 60mg m-2 and cykohosphamid 600mgm-2 within II weeks. Eight
patients were treated with 5-fluorouracil 700mg m-2, epirubidn 70 mg m-2 and cydophosphamide
700mg m2 and four had dose-limiting toxicity with sepsis, thrombocytopenia or mucositis. All patients who
received G-CSF had satisfactory neutrophil counts by day 15 of each course. Cumulative anae and
thrombocytopenia were obsrved, but treatment at the first dose was tolerable. Seven of eight patients with
measurable disease had partial responses. This regimen permits a 50% increase in dose intensity compared
with conventional treatment at 3 week intervals and warrants further evaluation.
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Although conventional combination chemotherapy produces
responses in 40-70% of women with advanced breast cancer
and prolongs survival in certain groups in the adjuvant set-
ting, overall the results of cytotoxic treatment for breast
cancer remain poor. The potential benefits of dose
intensification have been extensively discussed (Hryniuk et
al., 1984; Henderson et al., 1988). The observation ofdurable
complete responses following high-dose chemotherapy with
autologous bone marrow or peripheral blood progenitor cell
support is persuasive and encouraging (Eddy, 1992). The
results of randomised trials comparing high-dose and conven-
tional adjuvant chemotherapy in women with poor-prognosis
breast cancer are awaited with interest, and should clarify the
benefits (and costs) of such intensive therapy. However, it is
clear that high-dose chemotherapy is not appropriate for all
women with breast cancer who require adjuvant chemo-
therapy. An alternative strategy is dose intensiiation of
established chemotherapy combinations with haematopoietic
growth factor support. Several trials have shown that granu-
locyte colony-stimulating factor (G-CSP) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) can ameli-
orate or prevent chemotherapy-induced neutropenia (Bron-
chud et al., 1988; Groopman et al., 1989). In addition, for
chemotherapeutic regimens whose dose-limiting toxicity is
neutropenia, these growth factors can facilitate delivery of
conventional or higher doses of cytotoxic at shortened inter-
vals. Thus combinations of doxorubicin and cyclophospha-
mide (Bronchud et al., 1989), 5-fluorouracil, doxorubicin and
cyclophosphamide (van Hoef et al., 1994) and 5-fluorouracil,
epirubicin and cyclophosphamide (Ard1izoni et al., 1994)
have been successfully delivered at 2 week intervals with
growth factor support in women with advanced breast
cancer. However, other studies have found that such dose-
intensive regimens produce excessive toxicity (Ferguson et al.,
1993; Osborne et al., 1994), and the increase in dose intensity
has been limited to about 30%.
In this phase I study we have explored the dose
intensification of the combination of 5-fluorouracil,
epirubicin and cyclophosphamide given to women with




Eligible patients were women aged 18-60 years with histo-
logically confirmed carcinoma of the breast, either stage III
or IV, or stage II with more than four histologically positive
axillary lymph nodes. All patients were required to have a
WHO performance status of 0 or 1, and normal haemato-
logical and biochemical indices [Hb> 10 g dl-', absolute
neutrophil count (ANC)> 1.5 x 1091', platelet count
> IO00 X I I-1, biibin <17 mmolI'-i]. Prior endocrine
therapy was permitted but had to be withdrawn before enrol-
ment. Patients were excluded if they had received any
previous chemotherapy for advanced disease, adjuvant
chemotherapy within 12 months of study entry or any
previous anthracycine, and if they had concurrent cardiac
diseas. Written informed consent was obtained from all
patients and the study was approved by the local ethics
committee.
Study design and treatment
This was a single-entre phase I study carried out in the
Beatson Oncology Centre, Glasgow, UK. Cohorts of patients
were recruited to successive dose levels and there was no dose
esalation within each cohort The starting dose of chemo-
therapy was 5-fluorouracil 600mg m-2, epirubicin 60 mg
m-2, and cyclophosphamide 600mgm2 (FEC). In the first
cohort of patients the aim was to try to deliver this regimen
at 2 week intervals without G-CSF support. It was planned
that if any of six patients had dose-limiting toxicity then the
study would proceed with G-CSF support in all subsequent
cohorts. The second cohort received this regimen at 2 week
intervals with G-CSF (Chugai Pharmaceuticals, UK) admini-
stered by subcutaneous injection at a dose of 5 gsg kg-' daily
on days 2-14 of each treatment cycle (level A). The third
cohort received 5-fluorouracil 700 mgm2, epirubicin 70 mg
m-2 and cyclophosphamide 700 mg m-2 with G-CSF support
at 2 week intervals (level B). A minimum of three evaluable
patients had to complete two courses of treatment before
patients were recruited to the next dose level. The maximum
tolerable dose was exceeded when more than one-third of
patients treated at that dose level experienced dose-limiting
toxicity. Dose-limiting toxicity was defined as neutropenic
fever requiring hospitalisation, thrombocytopenia requiring
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platelet transfusion, WHO grade 3 mucositis, other toxicities
of WHO grade 2 or worse (excluding emesis and alopecia) or
delay in chemotherapy beyond the planned 2 week intervals.
Chemotherapy was delayed if the ANC was <1.0 x 1091-'
or the platelet count <100 x l0'1-', or if mucositis was
unresolved on the day of treatment. In patients who exper-
ienced dose-limiting toxicity, further chemotherapy was
delivered at 3 week intervals without G-CSF for the first two
cohorts, and at the lower dose level for the third cohort. The
planned duration of treatment was six courses over 12 weeks.
In patients with assessable disease response was assed after
three and six courses of chemotherapy. Patients were with-
drawn from study if they had disease progression or un-
acceptable toxicity or at the patient's request.
Prophylactic antiemetic therapy was prescnbed with each
course of chemotherapy and consisted of ondansetron 8 mg
i.v. and dexamethasone 8 mg i.v. imediately before chemo-
therapy, and dexamethasone 2 mgp.o. t.d.s. and domperid-
one 20mg p.o. t.d.s. for 3 days after chemotherapy. Pro-
phylactic antibiotics were not routinely prescribed, but a
mouthwash and nystatin suspenson were recommended in
patients with ANC<0.5 x 10' 1-. Platelet transfusions were
given when platelet counts fell below 13 x 1091' or when
less severe thrombocytopenia was accompanied by bleeding
or sepsis, and red blood cell transfusions were given when
Hb values fell below 9.5 gdl- . Paracetamol was admin-
istered as required for G-CSF-induced bone pain or fever.
Monitoring
Before study entry a clinical history, examination, chest
radiograph, electrocardiogram, echocardiogram, full blood
count, and serum chemistry were performed. In addition,
patients with measurab disease had tumour assessment
either clinically or radiologically. A liver ultrasound, isotope
bone scan and plain radiology of bone scan hotspots were
performed in patients with metastatic disease. During treat-
ment patients were seen weekly in the out-patient clinic to
assess treatment-related toxicity and to monitor full blood
counts and serum chemistry. Clinically assessable disease was
measured every 2 weeks and appropriate radiology repeated
after three courses of treatment. Following completion of
treatment or withdrawal from the study the baseline inves-
tigations were repeated.
Dose intensity calculation
The main objective of the study was to define the highest
tolerable dose intensity of the FEC regimen when six courses
were given at 2 week intervals with G-CSF support. Dose
intensity was cakulated for individual patients for all
received treatment, expressed for each drug in mgm-2 per
week, where the number ofweeks was counted from the first
day of cycle I to 14 days after the last day of chemotherapy
for the 2 weekly regimen and 21 days after the last day of
chemotherapy for the 3 weekly rgimen. The results were
analysed on an 'intent to treat' basis and comparison made
with 'conventional' FEC administered at the first dose level
at 3 week intervals.
Redls
Between July 1993 and April 1994, 17 patients entered the
study. Their characteristics are summarised in Table I. Three
patients received FEC at the first dose level without G-CSF
and all had the second treatment delayed until day 21
because ofneutropenia on day 15 (absolute neutrophil counts
0.68, 0.49 and 0.3 x 109 1-'). They were subsequently treated
at 3 week intervals outwith the study. Six patients were
treated at 2 week intervals with FEC level A, and eight
patients were treated with FEC level B. The number of
courses and the dose of chemotherapy delivered at each dose
level are listed in Table 11. Five of six patients completed the
six planned courses of treatment at level A and three ofeight


















































FWe 1 Profiks of the neutrophil (-) and platelet (A) counts
for one patient treated at level B.
at level B. Two patients at level A each had a single week's
delay during treatment, one for unresolved thrombocyto-
penia and the other for a chest infection. A dose reduction
was applied in two patients at level B because of dose-
limiting toxicity. Five patients were withdrawn from treat-
ment before completing six cycles because of intolerable
toxicity, and one at the request of the patient.
Treatment-related toxicity
The major toxicities experienced at the two dose levels are
sumarised in Table HI. Dose-limiting toxicity occurred in
four of eight patients treated at level B; two patients had
grade 3 sepsis, one grade 4 thrombocytopenia and one grade
3 mucositis. The toxicity of level A was tolerable, and this is
the dose level recommended for future studies.
Although grade 4 neutropenia was frequent at both dose
levels, this was short-lived, and in all patients who received
G-CSF the neutrophil count had recovered by the first day of
the next course of chemotherapy (median day 15 neutrophil
count 32.5 x 10' 1', range 6.4-98). Severe neutropenia
(<0.1 x 109 1'-l) occurred in two patients at level A and four
patients at level B. There was no evidence of cumulative
neutropenia during the course of treatment, and indeed the
day 8 neutrophil count tended to rise with continuing chemo-
therapy (Table IV). In contrast thrombocytopenia and
anaemia progressively worsened during the course of chemo-
therapy (Figure 1). Although no patient required platelet
transfusion, packed red cell transfusions were administered to
five out ofsix patients at level A and five out ofeight at level
B; the median number of units transfused was 4 (range
2-7).Ahdrie FEC CGCSF
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Table H Chemotherapy delivered
FEC dose Level A Lewl B
Number of patients started 6 8
Number of courses delivered 35 40
Number of courses per patient 6,6,6,5,6,6 3,6a,6,4b4,5,6,6
Number of courses delayed 2 0
Number of dose reductions 0 2
Median (range) total dose (mgm->)
5FU 3600 (3000-3600) 3500 (2100-4200)
Epirubicin 360 (300-360) 350 (210-420)
Cyclophosphamide 3600 (3000-3600) 3510 (2100-4200)
LbDose reduction to level A for one and two courses respectively.
Table m Chemotherapy releated toxicities
Thrombo- Nauseal
FEC dose level Neutropenia cytopenia vomiting Mucositis Sepsis Lethargy
WHO grade 1-2 3-4 1-2 3-4 1-2 3-4 1-2 3 1-2 3 1-2 3
Level A oa 5 3 2 3 0 1 0 4 2 6 0
Level B 1 6 4 3 5 1 2 1 0 2 8 0
aNumber of patients with specified grade as worst toxicity experieed in any course.
Table IV Myelosuppression by course number
Level A Level B
Median (range) Median (range) Median (range) Median (range)
day 8 day 8 day 8 day 8
Course neutrophils platelets neutrophils platelets
1 0.77 (0.5-5.96) 239 (162-256) 0.36 (0.01-2.85) 150 (76-228)
2 0.28 (0.12-0.7) 139 (74-188) 0.72 (0.03-3.51) 116 (48-216)
3 1.11 (0.07-1.13) 146 (102-172) 1.82 (0.01-2.91) 79 (51-207)
4 1.53 (0.51-2.96) 107 (49-146) 1.42 (0.5-5.87) 87 (32-128)
5 1.53 (0.03-4.12) 54 (27-240) 0.73 (0-26-3.09) 66 (20-111)
6 1.73 (0.08-5.48) 83 (33-128) 2.39 (0.63-4.8) 78 (45-161)
Only one patient at level B developed neutropenic sepsis
requiring intravenous antibiotics. A second patient at this
dose presented with fever and bilateral pulmonary infiltrates
in the presence of a normal neutrophil count 10 days after
the fourth course of chemotherapy. This patient had no
known metastatic disease. Despite intravenous broad-
spectrum antibiotics her condition deteriorated with worsen-
ing hypoxia and radiological evidence of progressive
pneumonia. Although bronchial washings were negative, a
presumptive diagnosis of Pnewnocystis pneumonia was made,
and following treatment with high-dose cotrnmoxazole she
mad a complete recovery. In the light of this unexpected
toxicity, the fall in lymphocyte count was examined for each
treatment course. Transient grade 4 lymphopenia occurred in
three patients (nine courses) at level A and in all eight
patients (22 courses) at level B, and there was evidence of
cumulative toxicity with continuing chemotherapy.
The other chemotherapy-related toxicities including nausea
and vomiting, mucositis, diarrhoea and aesthenia were
manageable and predictable. Reversible alopecia was univer-
sal. One patient had an episode of paroxysmal supraventri-
cular tachycardia after the fifth course of chemotherapy at
level A. She was withdrawn from the study but subsequently
had a normal echocardiogram and 24h electrocardiogram.
No other cardiac toxicity was recorded in the study.
In general the G-CSF injections were well tolerated. Four
patients had bone pain or 'flu-like' symptoms, and 11 had
elevation of alkaline phosphatase attributable to G-CSF
(seven grade 1, four grade 2).
Dose intensity analysis
The 'conventional' regimen, 5-fluorouracil 600 mg m
epirubicin 60 mg m-2, and cyclophosphamide 600 mg kg-2
administered at 3 week intervals for six courses, was arbit-
rarily assigned a relative dose intensity of 1.0. The median
dose intensity with FEC level A was 360mgm-2week-'
5-fluorouracil and cyclophosphamide and 36mgm-2week-'
epirubicin, equivalent to a relative dose intensity of 1.5. For
the four patients who completed treatment at level B, the
relative dose intensity achieved was 1.75.
Tunour response
Eight patients had assessable disease. Two patients treated at
level A and five treated at level B had a partial response to
chemotherapy, and one patient at the higher dose level had
stable disease. Four of the responses were in patients receiv-
ing neoadjuvant chemotherapy, and all four have subse-
quently undergone mastectomy and axillary clearance. Resi-
dual tumour was found in all the mastectomy specimens; the
numbers of positive lymph nodes divided by the number of
nodes examined were 1/11, 2/13, 14/21 and 12/13 nodes. The
duration of response in the three other responding patients
was 7, 10 and 12 months.
This study confirms that it is feasible to deliver up to six
courses of conventional doses of FEC chemotherapy to
breast cancer patients at intervals of 2 weeks with G-CSF
support. However, it is clear from this and other recent
studies that cumulative toxicities preclude accelerated dose
intensification beyond this level with either G-CSF or GM-
CSF. Although this level of dose intensification is small
relative to that achievable with autologous bone marrow or
peripheral blood stem cell support, a recent randomised
study has shown that accelerated delivery of chemotherapy
with GM-CSF may improve the response rate in advanced
breast cancer (Ardizzoni et al., 1994). The size of benefit
which may accrue from such acceleration of conventionalkcdsroaimdP FECwfthGPMF
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chemotherapy in the setting of adjuvant therapy for breast
cancer is uncertain. An alternative approach to dose
intensification may be to accelerate and escalate the dose of a
single agent which has little non-haematological toxicity, and
Lichtman et al. (1993) have recently reported that multiple
courses of cyclophosphamide 4.5 g m- can be administered
at 2 week intervals with GM-CSF.
Although haematopoietic growth factors are certainly
effective in ameliorating neutropema after chemotherapy, the
optimum timing and duration of their administration is un-
certain. The day 15 counts recorded in this study suggest that
G-CSF could safely be withdrawn before day 14, and other
studies have been able to achieve similar acceleration of
chemotherapy with growth factors administered only from
days 2 to 11 or days 2 to 8 of each course (Lichtman et al.,
1993; van Hoef et al.. 1994). Cumulative haematological
toxicities were dose limiting in our study. Although in the
future it is likely that thrombocytopenia may be abrogated
by the use of another cytokine, in the light of our observa-
tion of cumulative lymphopenia and a presumed case of
Pneumocstis pneumonia we would suggest that future
studies of accelerated chemotherapy should monitor altera-
tions in the circulating lymphocyte populations.
This approach to dose intensification is manageable in the
out-patient clinic and may be most appropriate to the adju-
vant setting, where modest increments in cytotoxic doses may
result in inproved survival (Wood et al., 1994). Further
studies are required to compare the efficacy of this regimen
with conventional chemotherapy.
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